IntraStem is a proprietary peptide-based intracellular delivery system with unrivalled efficiency.

It can be used for a wide range of cellular re-programming and gene therapy applications. 

At present, biomedical gene therapy approaches utilise viral vectors, such as lentiviruses, to’ transfect’ the cell with the intended genetic material eg gene. However, they have a number of limitations with restrict their applications, not least that they are very expensive to manufacture.

The IntraStem platform utilises combinations of novel peptide sequences to achieve major gains in transfection efficiency – both potency and viability. It is a next generation cell-penetrating peptide (CPP) technology, which allows the intracellular delivery of conjugated cargoes to modify cell behaviour. IntraStem overcomes the deficiency of existing CPP technologies to deliver their cargoes to nuclear and cytoplasmic targets efficiently.

IntraStem can be used to deliver nucleic acids (plasmid (p)DNA, mRNA and siRNA), enzymes, transcription factors, antibodies, and magnetic nanoparticles (MNPs) into cells at much higher levels than the current alternatives. Importantly, IntraStem exhibits low cell toxicity and so cells can be exposed without directly affecting their viability. It also offers benefits over electroporation (causes cell damage and is expensive) and virus–mediated delivery (biosafety and mutagenesis concerns).

The IntraStem system therefore has a broad range of potential applications including gene therapy and ex vivo cell therapy modification. For example, Intrastem can be used to generate induced pluripotent stem cells (iPSCs) that are free of the ethical issues and immune rejection problems associated with embryonic stem cells.

Locate is currently evaluating a number of new product opportunities for in-house development and potential new third party collaborations.